Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Direct Meds vs Noom

Noom costs $50 less a month, and both sell semaglutide and tirzepatide.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Direct Meds logo

Direct Meds

6.4
★★★☆☆3.2/5

Best for: compounded semaglutide at $249/month

Visit Direct Meds →
VS
Noom logo

Noom

6.7
★★★☆☆3.4/5

Best for: coaching bundled into the price rather than sold separately

Visit Noom →

If you are choosing between Direct Meds and Noom, the first difference is cost: Noom is $50 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Noom leads our six-part score, 6.7 to 6.4. One of the two has an FDA warning letter on record, covered below.

Direct Meds vs Noom price

Noom is the cheaper way in: $199 a month against $249 a month at Direct Meds. That is $50 less each month (20% lower), or about $600 over a year of treatment.

Drug by drug: Semaglutide is cheaper at Noom ($199 a month vs $249 a month); tirzepatide is cheaper at Direct Meds ($299 a month vs $349 a month).

Medications and formats

Both sell semaglutide and tirzepatide.

On format, Direct Meds prices compounded injections, while Noom prices brand-name pens and compounded injections.

If you want the FDA-approved brand rather than a compounded version, Noom is the only one of the two with a brand-name price.

Where each one treats patients

Neither Direct Meds nor Noom publishes the states it serves, so enter your state at the very start of each sign-up.

Pricing

Direct Meds

SublingualCompounded
$249/mo
semaglutide

'As low as $249' per month, on a 90-day supply billed monthly; some doses run as low as $237/mo.

InjectionCompounded
$297/mo
semaglutide

'As low as $297' per month ($9.58 a day), an 84-day three-pack billed monthly.

SublingualCompounded
$299/mo
tirzepatide

'As low as $299' per month ($9.65 a day) on a 90-day supply billed monthly. Down from $399 earlier.

InjectionCompounded
$399/mo
tirzepatide

'As low as $399' per month ($12.87 a day).

Noom

GLP-1Rx Program — brand semaglutide (Wegovy/Ozempic)Brand-name
$349/mo
semaglutide
GLP-1Rx Program — brand tirzepatide (Zepbound/Mounjaro)Brand-name
$349/mo
tirzepatide
Microdose GLP-1Rx — compounded semaglutideCompounded
$199/mo
semaglutide

What each price covers

Both prices cover the clinician visit.

Direct Meds' price also covers the medication itself and shipping, which Noom does not claim.

Noom's price also covers coaching, which Direct Meds does not claim.

Direct Meds is silent on lab work and coaching.

Noom is silent on the medication itself, shipping and lab work.

That matters most for the drug: unless Noom confirms otherwise, budget for medication on top of its listed price.

Direct Meds

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Noom

Covered by the monthly price

Medication

Not stated

Clinician visits

In the price

Shipping

Not stated

Lab work

Not stated

Coaching

In the price

Where each one scores higher

Overall, Noom scores 6.7 and Direct Meds 6.4 out of 10.

Direct Meds is stronger on support (7.0 vs 4.0).

Noom is stronger on value (4.4 vs 3.7) and trust & safety (6.5 vs 3.5).

Effectiveness, user experience and accessibility are within half a point.

How we score

Direct Meds

6.4/10

Overall

Noom

6.7/10

Value25%

3.7A
vs
B
4.4

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

3.5A
vs
B
6.5

Accessibility10%

5.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.0

FDA warning letters

The FDA sent Direct Meds a warning letter dated September 9, 2025 (letter 716822), and it is still open.

Noom has no FDA warning letter on record with us.

Features & Coverage

FeatureDirect MedsNoom
Starting Price$249/mo✓$199/mo
Features✓5 features2 features
States AvailableNot disclosedNot disclosed
Compounded✓ Yes✓ Yes
Brand Name—✓ Yes
FSA/HSA Accepted——
FDA Warning Letters1 letter✓None

About Direct Meds

The FDA sent Direct Meds a warning letter in September 2025 over misleading marketing, and customers have reported a documented pattern of unexpected 3-month commitment charges. We list the company with both disclosed in full; read the warnings and the cons first. Its products are compounded semaglutide and tirzepatide, sold from Utah in injection and sublingual form.

Read our full Direct Meds review →

About Noom

Noom is a behavioral weight loss app. It also prescribes GLP-1 medications through Noom Med.

Read our full Noom review →

Pros & Cons

Direct Meds

What we like

  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication, clinician visits and shipping

Watch-outs

  • Semaglutide costs $249 a month, 35% above the $184 median for compounded semaglutide across the sellers we compare
  • Tirzepatide costs $299 a month, 20% above the $250 median for compounded tirzepatide across the sellers we compare
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • The FDA has issued Direct Meds a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Noom

What we like

  • Semaglutide costs $199 a month, close to the $184 median for compounded semaglutide across the sellers we compare
  • Tirzepatide costs $349 a month, 72% below the $1249 median for brand-name tirzepatide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes clinician visits and coaching
  • We found no FDA warning letters issued to Noom

Watch-outs

  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Direct Meds

Direct Meds is where we would start, above all for compounded semaglutide at $249/month. Noom undercuts it by $50 a month, so if the monthly bill is what decides it, Noom is the pick. Noom fits better if coaching bundled into the price rather than sold separately is your priority.

Choose Direct Meds if…

You want compounded semaglutide at $249/month and an opening price near $249 a month.

Choose Noom if…

You want coaching bundled into the price rather than sold separately and an opening price near $199 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

5.9

Wellorithm

Compounded semaglutide at $247/month

6.6

Willow

Seeing what it charges before you answer any medical questions

6.5

Sesame Care

Oral orforglipron alongside the injectables

Direct Meds vs Noom: FAQ

Noom. It starts at $199 a month; Direct Meds starts at $249 a month, $50 more per month.
Yes, both sell semaglutide and tirzepatide.
Direct Meds does not publish where it ships; Noom does not publish where it ships. Confirm your state before paying.
Both include the clinician visit. Only Direct Meds includes the medication itself and shipping. Only Noom includes coaching.
Direct Meds has an open FDA warning letter from September 9, 2025. Noom has none.
Direct Meds pays us a commission on sign-ups through our links; Noom does not. Scores are computed the same way for both.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.